The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $194.72

Today's change+1.95 +1.01%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $194.72

Today's change+1.95 +1.01%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc up (U.S.)$1.95

Alexion Pharmaceuticals Inc closed up Wednesday by (U.S.)$1.95 or 1.01% to (U.S.)$194.72. Over the last five days, shares have gained 1.44% and are currently 1.48% off of the 52-week high. Shares have outperformed the S&P 500 by 45.04% during the last year.

Key company metrics

  • Open(U.S.) $193.28
  • Previous close(U.S.) $192.77
  • High(U.S.) $194.99
  • Low(U.S.) $191.52
  • Bid / Ask-- / --
  • YTD % change+46.53%
  • Volume704,468
  • Average volume (10-day)781,351
  • Average volume (1-month)880,452
  • Average volume (3-month)1,123,763
  • 52-week range(U.S.) $120.14 to (U.S.) $197.64
  • Beta0.71
  • Trailing P/E81.03×
  • P/E 1 year forward37.42×
  • Forward PEG1.22×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.40
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue555512567442
Total other revenue--------
Total revenue555512567442
Gross profit503473534390
Total cost of revenue52403352
Total operating expense318294357304
Selling / general / administrative158159129135
Research & development978918883
Depreciation / amortization3333
Interest expense (income), net operating--------
Unusual expense (income)82332
Other operating expenses, total--------
Operating income237219210138
Interest income (expense), net non-operating-----1-1
Gain (loss) on sale of assets--------
Other--------
Income before tax236219212138
Income after tax178166159-19
Income tax, total585253157
Net income178166159-19
Total adjustments to net income--------
Net income before extra. items178166159-19
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items178166159-19
Inc. avail. to common incl. extra. items178166159-19
Diluted net income178166159-19
Dilution adjustment00--0
Diluted weighted average shares201202202199
Diluted EPS excluding extraordinary itemsvalue per share0.880.830.79-0.10
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.910.830.800.01